Both DNA double-and single-strand break repair are highly coordinated processes utilizing signal transduction cascades and post-translational modifications such as phosphorylation, acetylation and ADP ribosylation. 'Drugable' targets within these networks have been identified that could potentially lead to novel therapeutic approaches within the oncology arena. Key regulators within these signalling cascades, such as DNA-dependent protein kinase, ataxia-telangiectasia mutated, checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2) and poly(ADPribose) polymerase, use either ATP or nicotinamide adenine dinucleotide for their enzymatic functions and are therefore readily accessible to small molecule inhibition at their catalytic sites. A range of highly potent and selective inhibitors of these DNA damage response pathways has now been identified through drug discovery efforts, with candidate molecules either approaching or already in clinical trials. This review will describe the small molecule inhibitors and drug discovery activities that focus on DNA break repair, along with the therapeutic rationale behind chemosensitization and the concept of synthetic lethality. We will also describe the emerging clinical data coming from this exciting new approach to targeted cancer therapy.
Introduction
Mammalian cells are constantly at risk of damage to their DNA from multiple sources (Jackson, 2001) , including ultraviolet light, ionizing radiation (IR) and reactive oxygen species. Approximately 1 Â 10 4 DNA lesions are generated in a metabolically active cell each day (Lindahl, 1993; Jackson, 2001) , the majority of which are DNA single-strand breaks (SSBs), although included are the highly cytotoxic DNA double-strand breaks (DSBs). In higher eukaryotes, genomic stability is absolutely essential for healthy functioning and survival since DNA damage may induce mutations and lead to cell death. Consequently, eukaryotic cells have evolved a number of mechanisms to monitor the integrity of their genome and repair any damaged DNA before cell cycle progression in a coordinated process that utilizes 'checkpoint' control (Hartwell and Weinert, 1989; Hoeijmakers, 2001 ).
An early event in tumorigenesis involves the abrogation of this integrated DNA damage response (DDR), resulting in an increase in genomic instability and with it an increase in mutation rate that facilitates cancer formation. This is clearly demonstrated in people with genetic instability disorders, such as Lynch syndrome or Li-Fraumeni syndrome, both of which are caused by defects in DDR genes and which result in significant increases in cancer incidence (Malkin et al., 1990; Srivastava et al., 1990; Lynch and de la Chapelle, 1999) .
Consistent with our understanding of the loss of DDR pathways in tumorigenesis is the observation that cancer cells (and precancerous cells) generally grow under conditions of greater levels of endogenous DNA damage than non-cancer cells (Bartkova et al., 2005a , b, Gorgoulis et al., 2005 . This is likely to result from the combination of defects in DDR, de-regulated proliferation and the circumvention of DNA damage-induced cell death signalling (Bartkova et al., 2005a; Gorgoulis et al., 2005) . To compensate, remaining DDR pathways may be induced (Muller et al., 1998) and this has been postulated to be responsible for the limited success of conventional (non-surgical) cancer treatment such as ionizing radiation and cytotoxic chemotherapy. One notable exception to this is the success of cisplatin therapy in testicular cancer, where it has been proposed that a specific repair activity (nucleotide excision repair) that removes platinum-induced DNA damage is at very low levels in this specific tumour type (Koberle et al., 1999) . However, few examples currently exist where tumour type sensitivities to particular DNA-damaging agents are so clearcut. In fact, there are examples where loss of a specific DDR pathway results in resistance to DNA-damaging agents, such as the resistance of mismatch repair-deficient tumours to monofunctional alkylating agents such as temozolomide (Fedier and Fink, 2004) .
Together, these two examples highlight the importance of a targeted approach to cancer therapy in which there is an understanding of both the DNA repair defects in the tumour to be treated and the most appropriate way to induce DNA damage. In an ideal situation, by inhibiting those remaining DDR pathways being relied upon by the cancer cells to repair endogenously induced damage, there might not even be a need for additional DNA-damaging agents, providing the maximum therapeutic index and a minimum of normal tissue collateral damage.
In this article, we will review the efforts that are ongoing to identify inhibitors of key components of the DNA DSB and SSB repair and signalling machineries (see Figure 1) .
Small molecule inhibition of DNA DSB repair and signalling
Three kinases involved in the detection, signalling and repair of DSBs are ataxia-telangiectasia mutated (ATM), ATM and Rad3 related (ATR) and DNAdependent protein kinase(DNA-PK) (Smith and Jackson, 2003; Abraham, 2004 ). These extremely large proteins (>250 kDa) belong to a family of six protein serine/threonine kinases, termed phosphatidylinositol 3-kinase related kinase (PIKKs), whose active sites are structurally different from classical protein kinases, and whose kinase domains more closely resemble those of the phosphatidylinositol 3-kinase family of phospholipid kinases. Classically, ATM and ATR are viewed as signalling to the cell cycle and apoptotic machinery in response to DNA damage (Abraham, 2001) , while DNA-PK is intimately involved in the repair of DSBs by the process termed as non-homologous end-joining . Although historically thought of as acting in independent pathways, emerging data are revealing that these kinases may in fact cross-talk and modulate the other's activation and thus subsequent downstream DDR processes (for example Riballo et al., 2004; Jazayeri et al., 2006; Stiff et al., 2006) .
Inhibitors of ATM and ATR
ATM responds rapidly to DNA DSB damage following a complex set of events that are not fully understood but which include autophosphorylation and targeting of the protein to DNA via the Mre11/Rad50/Nbs1 (MRN) complex (reviewed in Lavin and Kozlov, 2007) . Once activated, ATM fires signals off to key effector cell cycle and DNA-repair components, most notably p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2), p53 binding protein 1, histone 2AX and structural maintenance of chromosome 1, to elicit check point arrest or apoptotic activation (Kurz and LeesMiller, 2004) . For ATR, activation and recruitment at DSBs is dependent upon an interaction with the regulator protein ATRIP that facilitates association with replication protein A-ssDNA nucleoprotein complexes that arise at the sites of stalled replication forks (Zou and Elledge, 2003) . However, the complexity of what lies downstream of ATM and ATR was recently highlighted by the work of Matsuoka et al. (2007) where up to 700 downstream phosphorylation events were shown to be dependent upon ATM and ATR. These novel targets of ATM and ATR extend into a much Small molecule inhibitors of DNA repair pathways MJ O'Connor et al wider range of cellular processes than was initially contemplated such as growth control and intracellular trafficking. Since tumour cells show the characteristics of genomic instability and have defects in their responses to DNA damage, it can be argued that targeting the ATM and ATR signalling pathways may afford some level of a positive therapeutic index over healthy cells when used in combination with exogenous DNA DSB-inducing agents. Validation of this idea was initially borne out for ATM and ATR from the observations that the radio-and chemosensitizing effects of caffeine were elicited through inhibition (albeit fairly weak) of these two kinases (Sarkaria et al., 1999) . Caffeine had previously been shown to preferentially kill p53 mutant cells and consequently there has been interest in identifying more potent and selective agents (Powell et al., 1995) . Additional validation of this approach for ATR was shown (Nghiem et al., 2001 ) whereby G1-checkpoint-deficient cells were selectively sensitized through ATR inhibition to undergo premature chromatin condensation.
Other classes of PIKK inhibitor that have been identified to date came out of the knowledge that their active sites bear similarity to phosphoinositide-3 kinase. Hence the established phosphoinositide-3 kinase inhibitors LY294002 and wortmannin have been found to inhibit the PIKKs with differing degrees of activity (Sarkaria et al., 1998; Izzard et al., 1999) . Similar to caffeine, a lack of selectivity has hampered their use and development. Interestingly, the relatively non-specific LY294002 has gone on to be used successfully as a template for drug design to identify more selective and potent PIKK inhibitors (for example Hardcastle et al., 2005; Hollick et al., 2007) . Screening of a combinatorial library based on LY294002 identified a small molecule ATP competitive inhibitor of ATM, 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933) (Hickson et al., 2004) . This compound demonstrates low nanomolar activity and high selectivity for ATM. KU-55933 has been shown to effectively sensitize cancer cells to both IR and DNA DSB-inducing chemotherapeutics such as topoisomerase II inhibitors. More recently, in a cellular screen to identify compounds that would reverse the 'senescence clock', Won et al. (2006) found the thioureacontaining compound, CGK733, to be a potent inhibitor of both ATM and ATR with IC 50 s against both enzymes of B200 nM. Along with oncology and ageing, ATM has also been proposed as a target for human immunodeficiency virus therapy where it has been shown that KU-55933 was able to suppress the replication of both wild-type and drug-resistant human immunodeficiency virus (Lau et al., 2005) .
The majority of studies using caffeine, LY294002 and wortmannin have been focused on investigating the chemo-and/or radiopotentiating effects of these agents. This has been based on the assumption that inhibitors of DDR will not have any effect by themselves, since these pathways only become active in response to DNA damage. This assumption was elegantly challenged by Kennedy et al. (2007) who showed that inhibiting ATM was synthetically lethal with the Fanconi Anemia pathway. Loss of expression of a range of FANC genes has been reported in a variety of cancers, including head and neck, lung, ovarian and cervical cancer (Kennedy and d'Andrea, 2006) . Hence, pharmaceutical inhibition of ATM may provide the basis for the selective treatment of Fanconi Anemia pathway-deficient cancers.
Inhibitors of DNA-PK
While ATM and ATR act in the management and initiation of the DDR, DNA-PK is a mediator of the repair process itself that functions within the non-homologous end-joining pathway. Similar to cells defective in ATM and ATR, those cells lacking Ku (the DNA DSBtargeting components of DNA-PK) or the DNA-PK catalytic subunit (DNA-PKcs) are sensitive to IR and DSB-inducing chemotherapeutics (Jeggo, 1998) . As well as applying the aforementioned rationales for inhibiting ATM and ATR to DNA-PK, it has also been observed that overactivation of DNA-PK in cancers can occur, resulting in increased DNA damage resistance (Muller et al., 1998) . In clinical isolates of B-cell chronic lymphocytic leukaemia, the upregulation of DNA-PK activity impairs DNA damage-induced apoptosis. Hence, selective inhibition of DNA-PK may provide an opportunity to overcome this resistance mechanism. Interestingly, mutation of the ATM gene occurs in 12% of B-cell chronic lymphocytic leukaemia which may render these tumour cells more reliant on the remaining DNA-PK pathway for survival in response to DNA damage (Austen et al., 2005) .
As described above, initial investigations into targeting DNA-PK were based on the non-selective PIKK inhibitors, wortmannin and LY294002, and demonstrated the ability to sensitize tumour cells to IR and DSB-inducing chemotherapeutic agents. In a similar way in which novel ATM inhibitors were identified, LY294002 was also used as a starting point for medicinal chemistry to identify a potent and selective DNA-PK inhibitor (NU7441) with an IC 50 of 13 nM. NU7441 shows an excellent selectivity profile across the PIKKs and unrelated kinases and acts as a chemopotentiator both in vitro and in vivo (Zhao et al., 2006) . Ismail et al. (2004) reported on the identification of SU11752, from a 3-substituted indolin-2-one library, as a 130 nM ATP competitive inhibitor with radiosensitizing properties. This agent abrogates DNA DSB repair without modulating the cell cycle and does not significantly affect ATM function or phosphoinositide-3 kinaseg activity. Tumour radiosensitization has also recently been demonstrated in vitro and in vivo using IC87361, a reportedly more selective flavone-based DNA-PK inhibitor (Shinohara et al., 2005) .
The range of different selectivity profiles that these compounds possess highlights both the structural differences and similarities that must exist within the active sites of proteins within this kinase family. Consequently, it is clear that the potential exists for identifying specific inhibitors for each member of the PIKK family. Specific kinase inhibitors targeted towards ATM, ATR or DNA-PK will be of value in gaining greater insight into the pharmacological consequences of targeting individual PIKKs. Moreover, specific agents will harness our understanding of what therapeutic index and toxicological consequences may occur through PIKK inhibition in the oncology setting either alone or in combination with DNA-damaging agents. While well-validated inhibitors of ATM and DNA-PK now exist, there is currently no known specific inhibitor of ATR.
CHK1 and CHK2 inhibitors
Drug discovery programmes targeting CHK1 and CHK2 pre-dated those efforts targeting the PIKKs, and consequently a raft of CHK1 and CHK2 inhibitors have now been disclosed with four of the most advanced agents in Phase I clinical trials (Table 1, reviewed in Janetka et al., 2007) . Activated in response to DNA damage by ATM and ATR, these cell-cycle regulatory serine/threonine kinases coordinate the arrest of cell cycle progression. CHK1 regulates the S and G2/M checkpoints, while CHK2, solely activated via ATM, transduces signals to elicit an additional G1 arrest and, in certain situations, apoptosis (Bartek and Lukas, 2003) . CHK1 was identified as the target of the staurosporine analogue, UCN-01, which caused abrogation of the G2/M checkpoint in response to IR in p53-negative cells. This led to the rationale that targeting CHK1's S and G2/M checkpoint activity would lead to preferential sensitization of p53 mutant cancer cells to genotoxic agents. Cell line data validating this approach has emerged and the rationale is now being extended to the clinic with three agents (AZD7762, PF47736 and XL844) being evaluated in the Phase I setting in combination with gemcitabine. Gemcitabine appears to have been chosen based on preclinical data showing favourable potentiation of this agent's activity in vitro in cancer cell lines and in xenograft models (Janetka et al., 2007) . The Lilly/ICOS agent IC83 has recently been disclosed as entering a Phase I study in combination with Pemetrexed, although little in the way of preclinical data are available in the public domain at this time for IC83. As detailed in Table 1 , AZD7762, PF47736 and XL844 show a range of potencies against CHK2. With CHK2 activating the G1 checkpoint and apoptotic pathways, it has been hypothesized that CHK2 inhibition may lead to the enhanced effect of sensitizing p53-null cancer cells while protecting normal cells (Kawabe, 2004) . In support of this argument, Arienti et al. (2005) showed that an ATP-competitive inhibitor of CHK2 protected human CD4( þ ) and CD8( þ ) T cells from apoptosis following IR. Likewise, the CHK2 selective agent VRX0466617 attenuated IR-induced apoptosis in short-term assays, while having no effect on the cytotoxicity of doxorubicin, taxol or cisplatin (Carlessi et al., 2007) .
Small molecule inhibition of DNA SSB repair and signalling
The base-excision repair pathway and the role of PARP In mammalian cells, the main source of DNA SSB damage arises from oxygen radicals generated through normal cellular metabolic processes (Lindahl, 1993) . However, DNA SSBs can also be generated by exogenous agents such as alkylating agents and IR. The pathway that has evolved to detect and repair these DNA SSBs is known as the base-excision repair (BER) pathway. The BER pathway has been extensively studied and reviewed (Krokan and Slupphaug, 2007) . A key regulator of the BER process is poly(ADP-ribose) polymerase (PARP-1) which detects SSBs either induced directly by reactive oxygen species or generated through the enzymatic incision of an abasic site by AP endonuclease 1 (APE1) or a dual function DNA glycosylase. This is followed by the catalytic cleavage of nicotinamide adenine dinucleotide into nicotinamide and ADPribose with the latter being used by PARP to covalently modify itself with highly charged branched chains of poly(ADP-ribose) (PAR). It is believed that the main target of poly(ADP-ribosylation) is PARP-1 itself, and that this auto-modification serves to recruit other components of the BER pathway to facilitate SSB repair (D'Amours et al., 1999) . However, other potential targets of poly(ADP-ribosylation) include histones, transcription factors and other signalling molecules such as nuclear factor-kB, DNA-PK, p53, topoisomerase I and lamin B (reviewed in Virag and Szabo, 2002) . Inactivation and the recycling of PARP-1 protein is then facilitated by poly(ADP-ribose) glycohydrolase (Bonicalzi et al., 2005) . 
Inhibitors of PARP
In knockout mouse models, deletion of PARP-1 impairs DNA repair and results in increased sensitivity to DNAdamaging agents that induce DNA SSBs, without being embryonic lethal (de Murcia et al., 1997; Masutani et al., 2000) . Consistent with these findings are the data from a number of PARP inhibitors based on nicotinamide analogues, ranging from those with low micromolar activity, such as 3-aminobenzamide (Durkacz et al., 1980) to the more potent and specific PARP inhibitors that have been generated more recently (Southan and Szabo, 2003; Curtin, 2005; Farmer et al., 2005; Ratnam and Low, 2007) . Enhanced PARP-1 expression or activity has been observed in a number of different tumour cell lines (Tomoda et al., 1991; Shiobara et al., 2001 ) and could provide a greater level of resistance to both endogenous genotoxic stress, as well as to DNA damage-inducing therapeutic agents. Evidence that PARP inhibitors can sensitize tumour cells to cytotoxic therapies such as temozolomide, topoisomerase I inhibitors, platinums and radiation (for example Calabrese et al., 2004; Miknyoczki et al., 2003; Chalmers et al., 2004) has consequently provided sufficient interest for a number of these compounds to be developed as clinical candidates (see Table 2 and Plummer, 2005; Fong et al., 2006) . The first of these to be evaluated in humans for cancer therapy was AG-014699 (Plummer, 2005) , an i.v. formulation administered with temozolomide in solid tumours. This study was followed by a Phase II trial in metastatic melanoma patients, again in combination with temozolomide (Plummer, 2006) . While these studies reported an increase in the number of clinical responses, there was also an enhancement of temozolomide-related myelosuppression. This example highlights the difficulties of developing DNA repair inhibitors in the absence of any patient selection criteria based on tumour DNA repair status.
Induced cancer-specific synthetic lethality Ideally, in order to maximize the therapeutic index of DNA repair inhibitors, it may be necessary to define the tumour genetic background where those inhibitors exploit deficiencies in DNA damage pathways that occurred during tumorigenesis.
This concept of synthetic lethality, where two pathway defects alone can be tolerated but when combined become lethal, is not new and has been used very successfully in both Drosophila and yeast genetic studies (Lucchesi, 1968; Hartman et al., 2001) . However, in the oncology arena, the scenario where one pathway deficiency is tumour-specific and the second is induced with a DNA repair inhibitor has significant therapeutic potential (Kaelin, 2005) . A mechanistic understanding of SSB repair and homologous recombination (HR) repair-mediated DNA DSB repair, coupled with cell-based screens, led to the discovery that BRCA-deficient cells were exquisitely sensitive to PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005) . The BRCA1 and BRCA2 genes are associated with hereditary breast and ovarian cancer and play a pivotal role in the HR pathway, a highly accurate pathway involved in the repair of DNA DSBs. In a BRCA-deficient background, PARP inhibitors induced cell death following an increase in the number of chromosomal aberrations, while for wild-type or BRCA þ /À heterozygous cells, no such effect was seen (Farmer et al., 2005 (Yap, 2007) .
Other potential drug targets within the BER pathway Within the BER pathway, both upstream and downstream of PARP, a number of other components are involved in the repair process (Figure 2) . The DNA repair protein AP endonuclease1 (APE1) (also referred to as Ref1 due to its associated redox control of transcription factors) plays a central role in creating normal 3 0 -hydroxy groups and adjacent abasic deoxyribose-5-phosphates in DNA following damage. Activation of APE1 is essential for the protection of cells against toxic damage with overexpression of APE1 being linked to radio-and chemoresistance (for a review, see Evans et al., 2000) . Preventing the activation of APE1 through blockage of AP sites by methoxyamine is a novel area now being investigated with a view to Inhibitor of 3 0 phosphodiesterase and 3 0 -phosphatase activity of APE-1 Small molecule inhibitors of DNA repair pathways MJ O'Connor et al enhancing the effects of alkylating agents (Liu and Gerson, 2004) . Methoxyamine binds to the AP sites produced by the action of methylpurine glycosylase, an initial event in the processing of DNA damage within BER. These methoxyamine-bound AP sites are refractory to APE1 cleavage and block the BER pathway causing elevated levels of SSBs and eventual toxicity. Other agents identified to date that block the activity of APE1 are shown in Table 3 . The compound CRT0044876 was identified from a small chemical library screen and has been used to study the potentiation of cytotoxicity of DNA base-targeting agents through inhibiting APE1 DNA repair function (Madhusudan et al., 2005) , indicating that small molecule intervention of APE1 is achievable without severe cell toxicity.
Other BER components such as polynucleotide kinase1, polymerase b (Pol b) as well as Ligase III may all represent targets in their own right. Polynucleotide kinase 1 is not only involved in SSB repair through BER but also participates in non-homologous end-joining of DNA DSBs (Chappell et al., 2002 , Karimi-Busheri et al., 2007 . Pol b, in addition to its role in BER, plays a key role in translesion synthesis, providing tolerance to DNA damage during DNA replication in S phase. The overexpression of translesion synthesis polymerases, such as Pol b, may lead to an increased mutation rate and potentially act as an oncogene (Albertella et al., 2005b) . In addition, elevated levels of Pol b may also contribute to chemotherapeutic resistance seen for agents such as cisplatin (Albertella et al., 2005a) . Efforts to identify Pol b inhibitors are still at an early stage with pamoic acid being one of the more evaluated agents to date showing evidence of cellular activity (Hu et al., 2004) .
Summary
This review has attempted to highlight the different strategies that have emerged over the last decade or so to target DNA repair strand break mechanisms as the basis for novel oncology treatments. From directly inhibiting the repair processes, to abrogating cell cycle checkpoints, specific small molecule inhibitors have emerged from both academic and industrial groups. It is with great interest that we monitor the progress of this new generation of targeted therapies to see if they fulfil their potential in the clinic.
